3-(2-噻吩基）吡唑-4-甲醛 | 26033-27-2

• 物质功能分类: 医药中间体 - 噻吩类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-(2-噻吩基）吡唑-4-甲醛
• 中文别名: 3-(2-噻吩基)-1H-吡唑-4-甲醛；3-(2-噻吩基)吡唑-4-甲醛
• 英文名称: 3-(thiophen-2-yl)-1H-pyrazole-4-carbaldehyde
• 英文别名: 3-thiophen-2-yl-1(2)H-pyrazole-4-carbaldehyde；5-thiophen-2-yl-1H-pyrazole-4-carbaldehyde
• CAS: 26033-27-2
• 化学式: C₈H₆N₂OS
• mdl: MFCD02677688
• 分子量: 178.214
• InChiKey: DDQIKYLVCQKLHT-UHFFFAOYSA-N

物化性质

• 熔点：
  63-66°C
• 沸点：
  429.8±35.0 °C(Predicted)
• 密度：
  1.398±0.06 g/cm3 (20 ºC 760 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Name:	3-(2-Thienyl)-1H-pyrazole-4-carbaldehyde 97% Material Safety Data Sheet
Synonym:	3-(2-Thienyl)pyrazole-4-carboxaldehyd
CAS:	26033-27-2

Section 1 - Chemical Product MSDS Name:3-(2-Thienyl)-1H-pyrazole-4-carbaldehyde 97% Material Safety Data Sheet
Synonym:3-(2-Thienyl)pyrazole-4-carboxaldehyd

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
26033-27-2	3-(2-Thienyl)-1H-pyrazole-4-carbaldehy	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 26033-27-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 63 - 66 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H6N2OS
Molecular Weight: 178

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 26033-27-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(2-Thienyl)-1H-pyrazole-4-carbaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 26033-27-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 26033-27-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 26033-27-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(2-噻吩基）吡唑-4-甲醛 在 ALDH₂C₁ 、 nicotinamide adenine dinucleotide 作用下， 以 aq. buffer 为溶剂， 生成 3-(2-噻吩)-1H-吡唑-4-羧酸
  参考文献：
  名称：

  家族 2 和家族 10 的植物醛脱氢酶氧化咪唑和吡唑衍生的醛

  摘要：

  家族 2 的植物胞质醛脱氢酶（ALDH2，EC 1.2.1.3）是非特异性酶，参与乙醛的代谢或苯丙素的生物合成等。植物氨基醛脱氢酶（AMADH、ALDH10 家族、EC 1.2.1.19）具有广泛的特异性，在多胺降解或渗透保护剂的产生中发挥着重要作用。我们测试了咪唑和吡唑甲醛及其烷基、烯丙基、苄基、苯基、嘧啶基或噻吩基衍生物作为植物 ALDH2 和 ALDH10 酶的可能底物。咪唑是组氨酸、组胺以及某些生物碱的组成部分。它也出现在合成药物中，例如咪唑抗真菌剂。含有吡唑的生物化合物很少见（例如吡唑-1-丙氨酸和吡唑呋林抗生素），但该环经常作为许多合成药物和农药的成分被发现。目的是评估基于唑杂环的醛化合物是否被酶氧化，这将进一步支持它们作为解毒醛清除剂的预期作用。所分析的咪唑和吡唑甲醛仅被 ALDH10 缓慢转化，但被胞质玉米 ALDH2 异构体（特别是 ALDH2C1）充分氧化。在后一种情况下，各自的K

  DOI：

  10.1016/j.cbi.2019.02.008
• 作为产物：
  描述：

  2-乙酰基噻吩 在 sodium acetate 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 1.75h， 生成 3-(2-噻吩基）吡唑-4-甲醛
  参考文献：
  名称：

  3-取代的芳基吡唑-4-羧酸的合成

  摘要：

  提出了一种制备以前未知的3-芳基取代的吡唑-4-羧酸的方法，该方法包括将26种可用的单和双取代的苯乙酮和2-乙酰基噻吩的半咔唑的Vilsmeier甲酰化，然后氧化所得的3-芳基取代的吡唑-。 4-羧醛在高锰酸钾的作用下。讨论了甲酰化反应的机理。该方法即使对含有烷基取代基的苯乙酮也能成功地起作用。在后一种情况下，使用另外的步骤，该步骤涉及分离吡唑-4-羧酸作为其甲硅烷基酯。

  DOI：

  10.1007/s11176-005-0318-7

文献信息

• COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES
  申请人：Yuhan Corporation

  公开号：US20160102076A1

  公开（公告）日：2016-04-14

  The present invention provides a new group of protein kinase inhibitors, aminopyrimidine derivatives, and pharmaceutically acceptable salts thereof that are useful for treating cell proliferative disease and disorder such as cancer and immune disease. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefore. The invention also provides useful intermediates generated during the syntheses of the aminopyrimidine derivatives.

  本发明提供了一类新的蛋白激酶抑制剂，氨基嘧啶衍生物及其药用可接受的盐，用于治疗细胞增殖性疾病和紊乱，如癌症和免疫疾病。本发明提供了合成和给药蛋白激酶抑制剂化合物的方法。本发明还提供了包含至少一种蛋白激酶抑制剂化合物的药物配方，以及药用可接受的载体、稀释剂或辅料。该发明还提供了在合成氨基嘧啶衍生物过程中产生的有用中间体。
• Synthesis, Identification, and Structure–Activity Relationship Analysis of GATA4 and NKX2-5 Protein–Protein Interaction Modulators
  作者：Mikael Jumppanen、Sini M. Kinnunen、Mika J. Välimäki、Virpi Talman、Samuli Auno、Tanja Bruun、Gustav Boije af Gennäs、Henri Xhaard、Ingo B. Aumüller、Heikki Ruskoaho、Jari Yli-Kauhaluoma

  DOI：10.1021/acs.jmedchem.9b01086

  日期：2019.9.12

  cytotoxicity. The structure-activity relationship (SAR) analysis revealed that the aromatic isoxazole substituent in the southern part regulates the inhibition of GATA4-NKX2-5 transcriptional synergy. Moreover, inhibition of GATA4 transcriptional activity correlated with the reduced cell viability. In summary, comprehensive SAR analysis accompanied by data analysis successfully identified potent and selective

  转录因子GATA4和NKX2-5直接相互作用并协同激活几种心脏基因和牵张诱导的心肌肥大。以前，我们将苯基异恶唑羧酰胺1确定为命中化合物，该化合物可抑制GATA4-NKX2-5转录协同作用。在此，通过合成和表征220个衍生物和与结构相关的化合物，探索了1分子结构周围的化学空间。除了协同转录激活，还评估了所选化合物对GATA4和NKX2-5转录活性的影响以及潜在的细胞毒性。结构-活性关系（SAR）分析表明，南部的芳族异恶唑取代基可调节对GATA4-NKX2-5转录协同的抑制作用。而且，对GATA4转录活性的抑制与细胞活力的降低有关。总之，综合的SAR分析和数据分析成功地确定了GATA4-NKX2-5转录协同作用的有效和选择性抑制剂，并揭示了对其重要的结构特征。
• A New Synthetic Approach to Indazole Synthesis
  作者：Pier Giovanni Baraldi、Barbara Cacciari、Giampiero Spalluto、Romeo Romagnoli、Giovanni Braccioli、Zaid、Maria J. Pineda de las Infantas

  DOI：10.1055/s-1997-1328

  日期：1997.10

  Stobbe condensation of 3-alkyl- or aryl-4-formylpyrazoles 3a-f with diethyl succinate in the presence of potassium t-butoxide, followed by intramolecular ring closure (Ac2O-NaOAc), afforded the corresponding indazole derivatives 5a-f in 65-85% overall yield. These compounds are good starting materials for transformation to biologically active molecules, such as new pyrazole analogs of the left-hand segment of the potent natural antineoplastic agent CC-1065.

  3-烷基或芳基-4-甲酰基吡唑 3a-f 与二乙基梯酸在存在叔丁氧化钾的条件下进行 Stobbe 冷凝反应，随后通过分子内环合（Ac2O-NaOAc）生成相应的吲哚-并噁唑衍生物 5a-f，整体产率为 65-85%。这些化合物是转化为生物活性分子的良好起始材料，例如强效天然抗肿瘤剂 CC-1065 左侧片段的新吡唑类似物。
• HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor)
  申请人：GENESTE Herve

  公开号：US20080300260A1

  公开（公告）日：2008-12-04

  The present invention relates to heterocyclic compounds which are positive modulators of metabotropic glutamate receptor. The present invention also relates to the use of these compounds for preparing a pharmaceutical composition and to a method of treating a medical disorder, selected from neurological and psychiatric disorders associated with glutamate dysfunction.

  本发明涉及异环化合物，这些化合物是代谢型谷氨酸受体的阳性调节剂。本发明还涉及使用这些化合物制备药物组合物以及治疗神经系统和精神疾病的方法，这些疾病与谷氨酸功能障碍有关。
• Substituted anilinic piperidines as MCH selective antagonists
  申请人：Marzabadi R. Mohammad

  公开号：US20070043080A1

  公开（公告）日：2007-02-22

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

  本发明涉及选择性拮抗黑色素浓集激素-1（MCH1）受体的化合物。本发明提供了一种药物组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。本发明提供了一种由本发明化合物的治疗有效量和药学上可接受的载体组成的药物组合物。本发明还提供了一种制备药物组合物的方法，包括将本发明化合物的治疗有效量和药学上可接受的载体组合。